• How GCG Disrupts SARS-CoV-2 N Condensates

  2026-09-17

  The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a virus-relevant process and shows that (-)-gallocatechin gallate disrupts this condensation. Its combination of proteome-wide prediction, variant analysis, biochemical assays, and infection models provides a framework for studying antiviral mechanisms that target biomolecular condensates.

• Actinomycin D in Ybx1 RNA Stability Studies

  2026-09-17

  Actinomycin D is more than a cytotoxic transcriptional inhibitor: it is a temporal tool for testing RNA stability. This article explains how ActD can sharpen interpretation of the Ybx1–mRNA stability axis in cortical neurogenesis while controlling for transcriptional stress and apoptosis.

• AZD8055 Workflow for mTOR Pathway Studies

  2026-09-16

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and metabolic responses. This guide focuses on practical cell and animal workflow design while defining limits for aqueous formulations, clinical efficacy interpretation, and unsupported dose extrapolation.

• TJP3, Anoikis, and Breast Cancer Drug Resistance

  2026-09-16

  This study integrates anoikis-related gene profiling, machine-learning prognostic modeling, and experimental validation to identify breast cancer subgroups with distinct immune and chemotherapy-response features. TJP3 emerged as a candidate regulator associated with paclitaxel tolerance, migration, epithelial–mesenchymal transition markers, and potential immune escape, although the evidence remains largely associative and requires prospective validation.

• Ferrostatins, Lipid Damage, and Ferroptosis

  2026-09-15

  Skouta and colleagues showed that ferrostatin-1 protects cells by suppressing oxidative lipid damage rather than by broadly eliminating all reactive oxygen species. Their cross-model experiments connected lipid peroxidation with ferroptotic cell death and used mechanistic insight to guide the design of improved ferrostatin analogues.

• Iptacopan (LNP023) for Reliable Complement Assays

  2026-09-15

  Learn how Iptacopan (LNP023), supplied as SKU C8699, can help distinguish complement-dependent cell damage from direct cytotoxicity in viability and hemolysis workflows. This scenario-based guide connects factor B pharmacology with practical assay design, concentration selection, data interpretation, and product reliability.

• Proteinase K as a Protease Selectivity Benchmark

  2026-09-14

  Proteinase K is more than a routine digestion reagent: it can serve as a practical protease selectivity benchmark in molecular biology and inhibitor assays. This article connects SARS-CoV-2 3CLpro screening evidence with DNA workflow design, control selection, and preservation of nucleic acid quality.

• Vancomycin as a Strategic Tool in Translational Research

  2026-09-14

  Vancomycin is more than a conventional comparator: its defined peptidoglycan precursor binding mechanism makes it a powerful perturbation for MRSA, resistance, and Clostridium difficile infection research. This article connects mechanism, assay design, historical comparative evidence, product handling, and translational strategy.

• Otilonium Bromide: From Probe to Translation

  2026-09-13

  A mechanistic and translational framework for using Otilonium Bromide to interrogate cholinergic signaling, smooth muscle physiology, and neuroscience receptor modulation while maintaining rigorous boundaries between established evidence and forward-looking hypotheses.

• Epoxomicin as a Probe of Proteostasis Stress

  2026-09-12

  Epoxomicin is a selective, irreversible proteasome inhibitor that can reveal how protein quality control responds to endoplasmic reticulum stress. This article connects its chemistry to UBR1/UBR2 biology and provides an assay-centered framework for interpreting protein degradation and disease-model data.

• PP 2 (AG 1879) Src Signaling Workflows

  2026-09-11

  PP 2 (AG 1879) enables controlled interrogation of Src-family signaling in cancer, immune, and vascular models. This practical guide connects potency-aware dosing with reproducible workflows for proliferation, invasion, T-cell activation, and mechanistic validation.

• Aurora A Overexpression in High-Risk Retinoblastoma

  2026-09-11

  A 2024 study identifies Aurora kinase A overexpression as a frequent feature of retinoblastoma and links it to histopathologic factors associated with aggressive disease and poor chemotherapy response. By combining patient tissue analysis with genetic, pharmacologic, cellular, and xenograft models, the work supports AURKA as a biomarker-informed therapeutic target while highlighting the need for prospective validation.

• CK2 as a Translational Target: From Cancer to CIAV

  2026-09-10

  CX-4945 (Silmitasertib) offers a mechanistically grounded way to interrogate CK2 biology across oncology and host–virus research. This article connects CK2-dependent signaling, apoptosis, and cell-cycle control with new evidence that CIAV exploits host CK2α to stabilize VP2 and promote replication, while defining the experimental boundaries required for credible translation.

• (-)-Blebbistatin: NM II Inhibition Workflows

  2026-09-10

  Use (-)-Blebbistatin to separate non-muscle myosin II–dependent mechanics from channel-intrinsic excitability, with practical workflows spanning live-cell imaging, migration assays, and cardiac models. Its reversible, selective profile supports paired inhibition, washout, and temperature-challenge experiments rather than endpoint-only cytoskeletal measurements.

• GSTA1, Glutathione Depletion, and α-Amanitin Toxicity

  2026-09-09

  A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective detoxification enzyme. Integrated animal, cellular, transcriptomic, metabolomic, docking, and DARTS evidence indicates that α-amanitin-induced GSTA1 upregulation accelerates glutathione depletion and reactive oxygen species accumulation, highlighting GSTA1 as a mechanistically relevant target in acute liver injury research.

7962 records 1/531 page Next 12345 下5页 Last page